Produção Nacional
Revisado por pares
Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC–ESI-MS/MS: Application for a pharmacokinetic study with a levodopa/benserazide formulation
2011; Elsevier BV; Volume: 56; Issue: 5 Linguagem: Inglês
10.1016/j.jpba.2011.07.040
ISSN1873-264X
AutoresIsabela Costa César, Ricardo Martins Duarte Byrro, Fabiana Fernandes de Santana e Silva Cardoso, Iram Moreira Mundim, Leonardo de Souza Teixeira, Enikson Pontes da Silva, Sandro Antônio Gomes, Ricardo Rodrigues Bonfim, Gérson Antônio Pianetti,
Tópico(s)Parkinson's Disease Mechanisms and Treatments
ResumoA sensitive and simple method was developed for the quantitation of levodopa and its metabolite 3-O-methyldopa, in human plasma, after oral administration of tablet formulations containing levodopa (200 mg) and benserazide (50 mg). The analytes were extracted by a protein precipitation procedure, using carbidopa as an internal standard. A mobile phase consisting of 0.2% formic acid and acetonitrile (94:6, v/v) was used and chromatographic separation was achieved using ACE C18 column (50 mm × 4.6 mm i.d.; 5 μm particle size). Selected reaction monitoring was performed using the fragmentation transitions m/z 198 → m/z 107, m/z 212 → m/z 166 and m/z 227 → m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively. Calibration curves were constructed over the range 50.0–6000.0 ng/mL for levodopa and 25.0–4000.0 ng/mL for 3-O-methyldopa. The method shown to be specific, precise, accurate and provided recovery rates higher than 85% for all analytes. No matrix effect was detected in the samples. The validated method was applied in a pharmacokinetic study with a levodopa/benserazide tablet formulation in healthy volunteers.
Referência(s)